Figure 2.
PS-containing features on staurosporine-treated HUVECs bind lactadherin or annexin A5. Staurosporine-treated HUVECs were incubated with 10 nM lactadherin-488 (green) and annexin A5-Cy3 (red) and visualized with live-cell imaging. (A) Representative image of control, vehicle-treated HUVECs with differential interference contrast (gray scale) and fluorescence lactadherin (green) and annexin A5 (red) overlaid. Note the absence of either green or red fluorescence. (B) HUVECs pretreated for 15 minutes with 0.5 μM staurosporine before incubation with lactadherin and annexin A5. The representative image shows strong binding of lactadherin and annexin A5 to submicrometer scale structures with filopodialike (C) and punctate (D) structures. (C-D) Enlarged views of boxed regions in panel B showing individual and merged fluorescence signals.

PS-containing features on staurosporine-treated HUVECs bind lactadherin or annexin A5. Staurosporine-treated HUVECs were incubated with 10 nM lactadherin-488 (green) and annexin A5-Cy3 (red) and visualized with live-cell imaging. (A) Representative image of control, vehicle-treated HUVECs with differential interference contrast (gray scale) and fluorescence lactadherin (green) and annexin A5 (red) overlaid. Note the absence of either green or red fluorescence. (B) HUVECs pretreated for 15 minutes with 0.5 μM staurosporine before incubation with lactadherin and annexin A5. The representative image shows strong binding of lactadherin and annexin A5 to submicrometer scale structures with filopodialike (C) and punctate (D) structures. (C-D) Enlarged views of boxed regions in panel B showing individual and merged fluorescence signals.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal